#USA #Birmingham #Shilpa Medicare #Alveolus Bio #respiratory therapies

Alveolus Bio Secures Major Investment from Shilpa Medicare

Alveolus Bio, an innovative biotechnology firm spearheaded by Dr. Vivek Lal from the University of Alabama at Birmingham, has successfully completed a funding round led by Shilpa Medicare Limited, a prominent global pharmaceutical company. This strategic partnership positions Alveolus Bio to advance its revolutionary therapies for pulmonary diseases into Phase 2 clinical trials and initiate first-in-human studies.

Shilpa Medicare, known for its extensive expertise in developing and manufacturing therapeutic respiratory products, has now become the exclusive global partner for Alveolus Bio in the development and production of its respiratory therapies. This collaboration focuses on bringing Alveolus’s active pharmaceutical ingredient targeting chronic obstructive pulmonary disease (COPD) into impactful clinical phases.

The partnership brings to the table a wealth of knowledge regarding drug discovery, development, and regulatory expertise from Shilpa Medicare, which is crucial for navigating the complex pathways of clinical trials. Alveolus Bio aims to leverage this investment to expedite its clinical advances with its resMIT (respiratory microbiota-based inhaled therapeutics) platform. This cutting-edge technology allows for targeted delivery of inhaled treatments to the lungs, catering to unmet needs in conditions such as COPD, bronchopulmonary dysplasia (BPD), and pulmonary fibrosis.

"The arrival of Shilpa as a lead investor is a significant milestone for us," expressed Gaurav Mehta, CEO of Alveolus Bio. He emphasized that the global pharmaceutical leadership from Shilpa aligns perfectly with their vision to redefine treatment approaches for lung diseases.

Dr. C. Vivek Lal, the founder and Chief Scientific Officer of Alveolus Bio, echoed these sentiments, highlighting how the partnership combines groundbreaking biotechnology with world-class commercialization strategies. This alignment is expected to accelerate the delivery of life-changing therapies to the market.

According to Vishnukant Bhutada, Managing Director of Shilpa Medicare, the partnership enhances their portfolio of innovations, strengthening their role as a trusted global partner in biotechnology development. He remarked, "Shilpa has consistently focused on developing breakthrough biologics, and this collaboration with Alveolus Bio fortifies that commitment."

The funding round remains open for other strategic investors who share Alveolus Bio's vision to transform respiratory medicine into a more effective and innovative sector. Alveolus Bio is a subsidiary of Biostack Ventures, dedicated to creating superior therapies for lung diseases using the proprietary resMIT platform. Its pipeline encompasses treatments for conditions like COPD, BPD, cystic fibrosis, and more.

About Shilpa Medicare

Shilpa Medicare is a global pharmaceutical company that specializes in the end-to-end development and commercialization of drugs, particularly focusing on respiratory therapies and groundbreaking biotechnological innovations. For further information, visit Shilpa Medicare.

About Alveolus Bio

Founded by Dr. Vivek Lal, Alveolus Bio is focused on developing cutting-edge therapies for pulmonary diseases through its proprietary resMIT technology. It aims to address critical gaps in treatment options for diseases like COPD and pulmonary fibrosis.

This strategic investment not only signifies a leap forward for Alveolus Bio but also marks a critical point in the ongoing evolution of treatment strategies targeting respiratory conditions. The future of pulmonary therapies looks promising under this newfound collaboration.